{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:37:28Z","timestamp":1791074248842,"version":"4.1.0"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2007,10,3]],"date-time":"2007-10-03T00:00:00Z","timestamp":1191369600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1007\/s10549-007-9703-8","type":"journal-article","created":{"date-parts":[[2007,10,2]],"date-time":"2007-10-02T16:59:06Z","timestamp":1191344346000},"page":"91-103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The patient experience"],"prefix":"10.1007","volume":"105","author":[{"given":"Nadia","family":"Harbeck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Haidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,10,3]]},"reference":[{"key":"9703_CR1","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/annonc\/mdi146","volume":"16","author":"US Lehto","year":"2005","unstructured":"Lehto US, Ojanen M, Kellokumpu-Lehtinen P (2005) Predictors of quality of life in newly diagnosed melanoma and breast cancer patients. Ann Oncol 16:805\u2013816","journal-title":"Ann Oncol"},{"key":"9703_CR2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/bmj.38343.670868.D3","volume":"330","author":"C Burgess","year":"2005","unstructured":"Burgess C, Cornelius V, Love S, Graham J, Richards M, Ramirez A (2005) Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ 330:702","journal-title":"BMJ"},{"key":"9703_CR3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10865-005-9000-0","volume":"28","author":"KK Bennett","year":"2005","unstructured":"Bennett KK, Compas BE, Beckjord E, Glinder JG (2005) Self-blame and distress among women with newly diagnosed breast cancer. J Behav Med 28:313\u2013323","journal-title":"J Behav Med"},{"key":"9703_CR4","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0022-3999(02)00350-1","volume":"53","author":"C Nosarti","year":"2002","unstructured":"Nosarti C, Roberts JV, Crayford T, McKenzie K, David AS (2002) Early psychological adjustment in breast cancer patients: a prospective study. J Psychosom Res 53:1123\u20131130","journal-title":"J Psychosom Res"},{"key":"9703_CR5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1046\/j.1524-4741.2001.007001025.x","volume":"7","author":"C Koopman","year":"2001","unstructured":"Koopman C, Angell K, Turner-Cobb JM, Kreshka MA, Donnelly P, McCoy R, Turkseven A, Graddy K, Giese-Davis J, Spiegel D (2001) Distress, coping, and social support among rural women recently diagnosed with primary breast cancer. Breast J 7:25\u201333","journal-title":"Breast J"},{"key":"9703_CR6","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/pon.856","volume":"14","author":"J Turner","year":"2005","unstructured":"Turner J, Kelly B, Swanson C, Allison R, Wetzig N (2005) Psychosocial impact of newly diagnosed advanced breast cancer. Psychooncology 14:396\u2013407","journal-title":"Psychooncology"},{"key":"9703_CR7","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2005.05.130","volume":"23","author":"NE Avis","year":"2005","unstructured":"Avis NE, Crawford S, Manuel J (2005) Quality of life among younger women with breast cancer. J Clin Oncol 23:3322\u20133330","journal-title":"J Clin Oncol"},{"key":"9703_CR8","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1200\/JCO.2003.08.097","volume":"21","author":"PA Ganz","year":"2003","unstructured":"Ganz PA, Guadagnoli E, Landrum MB, Lash TL, Rakowski W, Silliman RA (2003) Breast cancer in older women: quality of life and psychosocial adjustment in the 15\u00a0months after diagnosis. J Clin Oncol 21:4027\u20134033","journal-title":"J Clin Oncol"},{"key":"9703_CR9","doi-asserted-by":"crossref","first-page":"376\u2013","DOI":"10.1093\/jnci\/djh060","volume":"96","author":"PA Ganz","year":"2004","unstructured":"Ganz PA, Kwan L, Stanton AL, Krupnick JL, Rowland JH, Meyerowitz BE, Bower JE, Belin TR (2004) Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. J Natl Cancer Inst 96:376\u2013387","journal-title":"J Natl Cancer Inst"},{"key":"9703_CR10","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-2648.2005.03524.x","volume":"51","author":"CG Vivar","year":"2005","unstructured":"Vivar CG, McQueen A (2005) Informational and emotional needs of long-term survivors of breast cancer. J Adv Nurs 51:520\u2013528","journal-title":"J Adv Nurs"},{"key":"9703_CR11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1369-6513.2001.00119.x","volume":"4","author":"EA Lobb","year":"2001","unstructured":"Lobb EA, Kenny DT, Butow PN, Tattersall MH (2001) Women\u2019s preferences for discussion of prognosis in early breast cancer. Health Expect 4:48\u201357","journal-title":"Health Expect"},{"key":"9703_CR12","first-page":"157","volume":"3","author":"AM Geiger","year":"2000","unstructured":"Geiger AM, Mullen ES, Sloman PA, Edgerton BW, Petitti DB (2000) Evaluation of a breast cancer patient information and support program. Eff Clin Pract 3:157\u2013165","journal-title":"Eff Clin Pract"},{"key":"9703_CR13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1188\/06.CJON.57-60","volume":"10","author":"JS Keller","year":"2006","unstructured":"Keller JS (2006) Implementation of a prechemotherapy educational intervention for women newly diagnosed with breast cancer. Clin J Oncol Nurs 10:57\u201360","journal-title":"Clin J Oncol Nurs"},{"key":"9703_CR14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ajmg.1501","volume":"103","author":"MJ Green","year":"2001","unstructured":"Green MJ, McInerney AM, Biesecker BB, Fost N (2001) Education about genetic testing for breast cancer susceptibility: patient preferences for a computer program or genetic counselor. Am J Med Genet 103:24\u201331","journal-title":"Am J Med Genet"},{"key":"9703_CR15","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.2741\/1926","volume":"11","author":"A Nicolini","year":"2006","unstructured":"Nicolini A, Carpi A, Tarro G (2006) Biomolecular markers of breast cancer. Front Biosci 11:1818\u20131843","journal-title":"Front Biosci"},{"issue":"Suppl 2","key":"9703_CR16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1634\/theoncologist.10-90002-30","volume":"10","author":"M van de Vijver","year":"2005","unstructured":"van de Vijver M (2005) Gene-expression profiling and the future of adjuvant therapy. Oncologist 10 (Suppl 2):30\u201334","journal-title":"Oncologist"},{"key":"9703_CR17","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/jnci\/93.12.913","volume":"93","author":"F J\u00e4nicke","year":"2001","unstructured":"J\u00e4nicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M; German N0 Study Group (2001) Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 93:913\u2013920","journal-title":"J Natl Cancer Inst"},{"key":"9703_CR18","first-page":"4617","volume":"62","author":"N Harbeck","year":"2002","unstructured":"Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Kruger A, Kiechle M, Janicke F, Schmitt M, Foekens JA (2002) Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n\u00a0=\u00a03424). Cancer Res 62: 4617\u20134622","journal-title":"Cancer Res"},{"key":"9703_CR19","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","volume":"415","author":"LJ van \u2018t Veer","year":"2002","unstructured":"van \u2018t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530\u2013536","journal-title":"Nature"},{"key":"9703_CR20","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A Multigene Assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817\u20132826","journal-title":"N Engl J Med"},{"key":"9703_CR21","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/jnci\/djj052","volume":"98","author":"C Sotiriou","year":"2006","unstructured":"Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262\u2013272","journal-title":"J Natl Cancer Inst"},{"key":"9703_CR22","doi-asserted-by":"crossref","first-page":"8431","DOI":"10.1073\/pnas.0401736101","volume":"101","author":"J Pittman","year":"2004","unstructured":"Pittman J, Huang E, Dressman H, Horng CF, Cheng SH, Tsou MH, Chen CM, Bild A, Iversen ES, Huang AT, Nevins JR, West M (2004) Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci USA 101:8431\u20138436","journal-title":"Proc Natl Acad Sci USA"},{"key":"9703_CR23","unstructured":"Adjuvant! Online. Decision making tools for health care professionals. http:\/\/www.adjuvantonline.com Cited 17 January 2007"},{"key":"9703_CR24","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2001.19.4.980","volume":"19","author":"PM Ravdin","year":"2001","unstructured":"Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980\u2013991","journal-title":"J Clin Oncol"},{"key":"9703_CR25","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/pon.1040","volume":"15","author":"LA Siminoff","year":"2006","unstructured":"Siminoff LA, Gordon NH, Silverman P, Budd T, Ravdin PM (2006) A decision aid to assist in adjuvant therapy choices for breast cancer. Psychooncology 15:1001\u20131013","journal-title":"Psychooncology"},{"key":"9703_CR26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/bcr1396","volume":"8","author":"R Warren","year":"2006","unstructured":"Warren R, Eleti A (2006) Overdiagnosis and overtreatment of breast cancer: is overdiagnosis an issue for radiologists? Breast Cancer Res 8:205","journal-title":"Breast Cancer Res"},{"key":"9703_CR27","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/bcr1397","volume":"8","author":"JL Jones","year":"2006","unstructured":"Jones JL (2006) Overdiagnosis and overtreatment of breast cancer: progression of ductal carcinoma in\u00a0situ: the pathological perspective. Breast Cancer Res 8:204","journal-title":"Breast Cancer Res"},{"key":"9703_CR28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/bcr1346","volume":"7","author":"AS Kumar","year":"2005","unstructured":"Kumar AS, Bhatia V, Henderson IC (2005) Overdiagnosis and overtreatment of breast cancer: rates of ductal carcinoma in\u00a0situ: a US perspective. Breast Cancer Res 7:271\u2013275","journal-title":"Breast Cancer Res"},{"key":"9703_CR29","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/bcr1314","volume":"7","author":"S Moss","year":"2005","unstructured":"Moss S (2005) Overdiagnosis and overtreatment of breast cancer: overdiagnosis in randomised controlled trials of breast cancer screening. Breast Cancer Res 7:230\u2013234","journal-title":"Breast Cancer Res"},{"key":"9703_CR30","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/bcr1354","volume":"7","author":"SW Duffy","year":"2005","unstructured":"Duffy SW, Agbaje O, Tabar L, Vitak B, Bjurstam N, Bjorneld L, Myles JP, Warwick J (2005) Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Res 7:258\u2013265","journal-title":"Breast Cancer Res"},{"key":"9703_CR31","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/jnci\/95.8.581","volume":"95","author":"T Whelan","year":"2003","unstructured":"Whelan T, Sawka C, Levine M, Gafni A, Reyno L, Willan A, Julian J, Dent S, Abu-Zahra H, Chouinard E, Tozer R, Pritchard K, Bodendorfer I (2003) Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. J Natl Cancer Inst 95:581\u2013587","journal-title":"J Natl Cancer Inst"},{"key":"9703_CR32","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1001\/jama.292.4.435","volume":"28;292","author":"T Whelan","year":"2004","unstructured":"Whelan T, Levine M, Willan A, Gafni A, Sanders K, Mirsky D, Chambers S, O\u2019Brien MA, Reid S, Dubois S (2004) Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery: a randomized trial. JAMA 28;292:435\u2013441","journal-title":"JAMA"},{"key":"9703_CR33","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1200\/JCO.2002.20.4.1008","volume":"20","author":"W Liang","year":"2002","unstructured":"Liang W, Burnett CB, Rowland JH, Meropol NJ, Eggert L, Hwang YT, Silliman RA, Weeks JC, Mandelblatt JS (2002) Communication between physicians and older women with localized breast cancer: implications for treatment and patient satisfaction. J Clin Oncol 20:1008\u20131016","journal-title":"J Clin Oncol"},{"key":"9703_CR34","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00520-002-0370-3","volume":"10","author":"RE Gray","year":"2002","unstructured":"Gray RE, Goel V, Fitch MI, Franssen E, Labrecque M (2002) Supportive care provided by physicians and nurses to women with breast cancer. Results from a population-based survey. Support Care Cancer 10:647\u2013652","journal-title":"Support Care Cancer"},{"key":"9703_CR35","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/bmj.38753.524201.7C","volume":"22;332","author":"A Esquivel","year":"2006","unstructured":"Esquivel A, Meric-Bernstam F, Bernstam EV (2006) Accuracy and self correction of information received from an internet breast cancer list: content analysis. BMJ 22;332:939\u2013942","journal-title":"BMJ"},{"key":"9703_CR36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0738-3991(03)00116-2","volume":"53","author":"L Rozmovits","year":"2004","unstructured":"Rozmovits L, Ziebland S (2004) What do patients with prostate or breast cancer want from an Internet site? A qualitative study of information needs. Patient Educ Couns 53:57\u201364","journal-title":"Patient Educ Couns"},{"key":"9703_CR37","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/cncr.11174","volume":"97","author":"AJ Winzelberg","year":"2003","unstructured":"Winzelberg AJ, Classen C, Alpers GW, Roberts H, Koopman C, Adams RE, Ernst H, Dev P, Taylor CB (2003) Evaluation of an internet support group for women with primary breast cancer. Cancer 97:1164\u20131173","journal-title":"Cancer"},{"key":"9703_CR38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2354.2000.00198.x","volume":"9","author":"N Rankin","year":"2000","unstructured":"Rankin N, Newell S, Sanson-Fisher R, Girgis A (2000) Consumer participation in the development of psychosocial clinical practice guidelines: opinions of women with breast cancer. Eur J Cancer Care (Engl) 9:97\u2013104","journal-title":"Eur J Cancer Care (Engl)"},{"key":"9703_CR39","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.pec.2004.09.009","volume":"57","author":"JB Mallinger","year":"2005","unstructured":"Mallinger JB, Griggs JJ, Shields CG (2005) Patient-centered care and breast cancer survivors\u2019 satisfaction with information. Patient Educ Couns 57:342\u2013349","journal-title":"Patient Educ Couns"},{"key":"9703_CR40","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1475-6773.2005.00383.x","volume":"40","author":"PM Lantz","year":"2005","unstructured":"Lantz PM, Janz NK, Fagerlin A, Schwartz K, Liu L, Lakhani I, Salem B, Katz SJ (2005) Satisfaction with surgery outcomes and the decision process in a population-based sample of women with breast cancer. Health Serv Res 40:745\u2013767","journal-title":"Health Serv Res"},{"key":"9703_CR41","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10549-006-9309-6","volume":"102","author":"B Sabo","year":"2007","unstructured":"Sabo B, St-Jacques N, Rayson D (2007) The decision-making experience among women diagnosed with stage I and II breast cancer. Breast Cancer Res Treat 102:51\u201359","journal-title":"Breast Cancer Res Treat"},{"issue":"18S","key":"9703_CR42","first-page":"321s","volume":"24","author":"G Oskay-Oezcelik","year":"2006","unstructured":"Oskay-Oezcelik G, Lehmacher W, Mirz R, Christ H, Kaufmann M, Bamberg M, Werner L, Wallwiener D, Overkamp F, Hindenburg HJ, Sehouli J (2006) What do adjuvant and metastatic breast cancer patients (BC) expect from their doctors? Final results of a German survey in 617 patients. J Clin Oncol 24(18S):321s. Abstract 6085","journal-title":"J Clin Oncol"},{"key":"9703_CR43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10549-006-9178-z","volume":"99","author":"SJ Jansen","year":"2006","unstructured":"Jansen SJ, Otten W, Stiggelbout AM (2006) Factors affecting patients\u2019 perceptions of choice regarding adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 99:35\u201345","journal-title":"Breast Cancer Res Treat"},{"key":"9703_CR44","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/pon.750","volume":"13","author":"KT Ashing-Giwa","year":"2004","unstructured":"Ashing-Giwa KT, Padilla G, Tejero J, Kraemer J, Wright K, Coscarelli A, Clayton S, Williams I, Hills D (2004) Understanding the breast cancer experience of women: a qualitative study of African American, Asian American, Latina and Caucasian cancer survivors. Psychooncology 13:408\u2013428","journal-title":"Psychooncology"},{"issue":"42","key":"9703_CR45","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3810\/pgm.2004.10.1598","volume":"116","author":"NJ McCarthy","year":"2004","unstructured":"McCarthy NJ (2004) Care of the breast cancer survivor: increased survival rates present a new set of challenges. Postgrad Med 116:39\u201340, 42, 45\u201346","journal-title":"Postgrad Med"},{"key":"9703_CR46","first-page":"211","volume":"3","author":"E Mrozek","year":"2005","unstructured":"Mrozek E, Shapiro CL (2005) Survivorship and complications of treatment in breast cancer. Clin Adv Hematol Oncol 3:211\u2013238","journal-title":"Clin Adv Hematol Oncol"},{"key":"9703_CR47","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/sj.bjc.6602075","volume":"91","author":"J Fracheboud","year":"2004","unstructured":"Fracheboud J, Otto SJ, van Dijck JA, Broeders MJ, Verbeek AL, de Koning HJ; National Evaluation Team for Breast cancer screening (NETB) (2004) Decreased rates of advanced breast cancer due to mammography screening in The Netherlands. Br J Cancer 91:861\u2013867","journal-title":"Br J Cancer"},{"key":"9703_CR48","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/sj.bjc.6602395","volume":"92","author":"S Moss","year":"2005","unstructured":"Moss S, Waller M, Anderson TJ, Cuckle H; Trial Management Group (2005) Randomised controlled trial of mammographic screening in women from age 40: predicted mortality based on surrogate outcome measures. Br J Cancer 92:955\u2013960","journal-title":"Br J Cancer"},{"key":"9703_CR49","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jama.293.10.1245","volume":"293","author":"JG Elmore","year":"2005","unstructured":"Elmore JG, Armstrong K, Lehman CD, Fletcher SW (2005) Screening for breast cancer. JAMA 293:1245\u20131256","journal-title":"JAMA"},{"key":"9703_CR50","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","volume":"365","author":"ATAC Trialists\u2019 Group","year":"2005","unstructured":"Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS; ATAC Trialists\u2019 Group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5\u00a0years\u2019 adjuvant treatment for breast cancer. Lancet 365:60\u201362","journal-title":"Lancet"},{"key":"9703_CR51","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","volume":"353","author":"B Thurlimann","year":"2005","unstructured":"Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A; for the Breast International Group (BIG) 1\u201398 Collaborative Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747\u20132757","journal-title":"N Engl J Med"},{"key":"9703_CR52","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","volume":"350","author":"RC Coombes","year":"2004","unstructured":"Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM; Intergroup Exemestane Study (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081\u20131092. Erratum in: N Engl J Med 2004; 351:2461","journal-title":"N Engl J Med"},{"issue":"18S","key":"9703_CR53","first-page":"933s","volume":"24","author":"RC Coombes","year":"2006","unstructured":"Coombes RC, Paridaens R, Jassem J, Van de Velde CJ, Delozier T, Jones SE, Hall E, Kilburn LS, Snowdon CF, Bliss JM, for the Intergroup Exemestane Study (IES) (2006) First mature analysis of the Intergroup Exemestane Study. J Clin Oncol 24(18S):933s. Abstract LBA527","journal-title":"J Clin Oncol"},{"key":"9703_CR54","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.1996.14.10.2738","volume":"14","author":"T Saphner","year":"1996","unstructured":"Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738\u20132746","journal-title":"J Clin Oncol"},{"key":"9703_CR55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10549-004-3777-3","volume":"90","author":"WF Anderson","year":"2005","unstructured":"Anderson WF, Jatoi I, Devesa SS (2005) Distinct breast cancer incidence and prognostic patterns in the NCI\u2019s SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat 90:127\u2013137","journal-title":"Breast Cancer Res Treat"},{"key":"9703_CR56","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687\u20131717","journal-title":"Lancet"},{"key":"9703_CR57","first-page":"362","volume":"41","author":"SE Ward","year":"1992","unstructured":"Ward SE, Viergutz G, Tormey D, deMuth J, Paulen A (1992) Patients\u2019 reactions to completion of adjuvant breast cancer therapy. Nurs Res 41:362\u2013366","journal-title":"Nurs Res"},{"key":"9703_CR58","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0033-3182(98)71356-8","volume":"39","author":"BL Green","year":"1998","unstructured":"Green BL, Rowland JH, Krupnick JL, Epstein SA, Stockton P, Stern NM, Spertus IL, Steakley C (1998) Prevalence of posttraumatic stress disorder in women with breast cancer. Psychosomatics 39:102\u2013111","journal-title":"Psychosomatics"},{"key":"9703_CR59","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10549-006-9207-y","volume":"99","author":"JN Ingle","year":"2006","unstructured":"Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE (2006) Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 99:295\u2013300","journal-title":"Breast Cancer Res Treat"},{"key":"9703_CR60","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.breast.2005.08.012","volume":"14","author":"L Fallowfield","year":"2005","unstructured":"Fallowfield L (2005) Acceptance of adjuvant therapy and quality of life issues. Breast 14:612\u2013616","journal-title":"Breast"},{"key":"9703_CR61","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","volume":"86","author":"B Fisher","year":"1994","unstructured":"Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527\u2013537","journal-title":"J Natl Cancer Inst"},{"key":"9703_CR62","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/jnci\/88.21.1529","volume":"88","author":"B Fisher","year":"1996","unstructured":"Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529\u20131542","journal-title":"J Natl Cancer Inst"},{"key":"9703_CR63","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/jnci\/93.9.684","volume":"93","author":"B Fisher","year":"2001","unstructured":"Fisher B, Dignam J, Bryant J, Wolmark N (2001) Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93:684\u2013690","journal-title":"J Natl Cancer Inst"},{"key":"9703_CR64","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0960-0760(01)00050-4","volume":"76","author":"AS Bhatnagar","year":"2001","unstructured":"Bhatnagar AS, Brodie AM, Long BJ, Evans DB, Miller WR (2001) Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J Steroid Biochem Mol Biol 76:199\u2013202","journal-title":"J Steroid Biochem Mol Biol"},{"key":"9703_CR65","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1023\/A:1008226721932","volume":"9","author":"M Gershanovich","year":"1998","unstructured":"Gershanovich M, Chaudri HA, Campos D, Lurie H, Bonaventura A, Jeffrey M, Buzzi F, Bodrogi I, Ludwig H, Reichardt P, O\u2019Higgins N, Romieu G, Friederich P, Lassus M (1998) Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5\u00a0mg daily, 0.5\u00a0mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR\/BC3). Ann Oncol 9:639\u2013645","journal-title":"Ann Oncol"},{"key":"9703_CR66","unstructured":"NCCN Practice Guidelines in Oncology\u2014Breast Cancer. v.2.2006. http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/breast.pdf Cited 17 January 2007"},{"key":"9703_CR67","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1054\/bjoc.2001.1733","volume":"84","author":"EA Grunfeld","year":"2001","unstructured":"Grunfeld EA, Ramirez AJ, Maher EJ, Peach D, Young T, Albery IP, Richards MA (2001) Chemotherapy for advanced breast cancer: what influences oncologists\u2019 decision-making? Br J Cancer 84:1172\u20131178","journal-title":"Br J Cancer"},{"key":"9703_CR68","first-page":"CD003368","volume":"19;3","author":"D Jones","year":"2006","unstructured":"Jones D, Ghersi D, Wilcken N (2006) Addition of drug\/s to a chemotherapy regimen for metastatic breast cancer. Cochrane Database Syst Rev 19;3:CD003368","journal-title":"Cochrane Database Syst Rev"},{"key":"9703_CR69","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1200\/JCO.2004.02.037","volume":"22","author":"European Organization for Research, Treatment of Cancer Breast Cancer Group","year":"2004","unstructured":"Bottomley A, Biganzoli L, Cufer T, Coleman RE, Coens C, Efficace F, Calvert HA, Gamucci T, Twelves C, Fargeot P, Piccart M; European Organization for Research, Treatment of Cancer Breast Cancer Group (2004) Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study. J Clin Oncol 22:2576\u20132586","journal-title":"J Clin Oncol"},{"key":"9703_CR70","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.bjc.6601883","volume":"91","author":"E Baldini","year":"2004","unstructured":"Baldini E, Prochilo T, Salvadori B, Bolognesi A, Aldrighetti D, Venturini M, Rosso R, Carnino F, Gallo L, Giannessi P, Conte PF, Orlandini C, Bruzzi P (2004) Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety. Br J Cancer 91:45\u201349","journal-title":"Br J Cancer"},{"key":"9703_CR71","first-page":"CD002747","volume":"2","author":"N Wilcken","year":"2003","unstructured":"Wilcken N, Hornbuckle J, Ghersi D (2003) Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2:CD002747","journal-title":"Cochrane Database Syst Rev"},{"key":"9703_CR72","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.1998.16.2.453","volume":"16","author":"P Dombernowsky","year":"1998","unstructured":"Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453\u2013461","journal-title":"J Clin Oncol"},{"key":"9703_CR73","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1200\/JCO.2001.19.14.3357","volume":"19","author":"A Buzdar","year":"2001","unstructured":"Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, Porter L, Nabholtz J, Xiang X, Brady C (2001) Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 19:3357\u20133366","journal-title":"J Clin Oncol"},{"key":"9703_CR74","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2003.04.194","volume":"21","author":"H Mouridsen","year":"2003","unstructured":"Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P, Bhatnagar A (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2101\u20132109","journal-title":"J Clin Oncol"},{"key":"9703_CR75","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/annonc\/mdi275","volume":"16","author":"W Irish","year":"2005","unstructured":"Irish W, Sherrill B, Cole B, Gard C, Glendenning GA, Mouridsen H (2005) Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer. Ann Oncol 16:1458\u20131462","journal-title":"Ann Oncol"},{"key":"9703_CR76","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1634\/theoncologist.9-5-489","volume":"9","author":"H Mouridsen","year":"2004","unstructured":"Mouridsen H, Sun Y, Gershanovich M, Perez-Carrion R, Becquart D, Chaudri-Ross HA, Lang R (2004) Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability. Oncologist 9:489\u2013496","journal-title":"Oncologist"},{"key":"9703_CR77","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/S0959-8049(03)00630-0","volume":"39","author":"C Rose","year":"2003","unstructured":"Rose C, Vtoraya O, Pluzanska A, Davidson N, Gershanovich M, Thomas R, Johnson S, Caicedo JJ, Gervasio H, Manikhas G, Ben Ayed F, Burdette-Radoux S, Chaudri-Ross HA, Lang R (2003) An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 39:2318\u20132327","journal-title":"Eur J Cancer"},{"key":"9703_CR78","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.clon.2004.06.023","volume":"16","author":"R Thomas","year":"2004","unstructured":"Thomas R, Godwardx S, Makris A, Bloomfieldk D, Moody AM, Williams M (2004) Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole. Clin Oncol 16:485\u2013491","journal-title":"Clin Oncol"},{"key":"9703_CR79","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3816\/CBC.2005.n.027","volume":"6","author":"A Brufsky","year":"2005","unstructured":"Brufsky A, Lembersky B, Schiffman K, Lieberman G, Paton VE (2005) Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer. Clin Breast Cancer 6:247\u2013252","journal-title":"Clin Breast Cancer"},{"key":"9703_CR80","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1158\/1078-0432.CCR-04-2569","volume":"11","author":"M De Laurentiis","year":"2005","unstructured":"De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D\u2019Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De Placido S (2005) A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11:4741\u20134748","journal-title":"Clin Cancer Res"},{"key":"9703_CR81","first-page":"1163","volume":"9","author":"L Witters","year":"2002","unstructured":"Witters L, Engle L, Lipton A (2002) Restoration of estrogen responsiveness by blocking the HER-2\/neu pathway. Oncol Rep 9:1163\u20131166","journal-title":"Oncol Rep"},{"key":"9703_CR82","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10549-006-9307-8","volume":"102","author":"PK Marcom","year":"2007","unstructured":"Marcom PK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Novielli N, Mann G, Tao Y, Ellis MJ (2007) The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 102:43\u201349","journal-title":"Breast Cancer Res Treat"},{"key":"9703_CR83","unstructured":"Kaufman B (2006) Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2-positive, hormone-dependent metastatic breast cancer (MBC). Presented at the 31st European Society for Medical Oncology Congress, Istanbul, Turkey, 27 September\u20133 October 2006. Abstract LBA2"},{"key":"9703_CR84","unstructured":"Study comparing GW572016 and letrozole versus letrozole in subjects with advanced or metastatic breast cancer. http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00073528. Cited 17 January 2007"},{"key":"9703_CR85","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(05)70254-0","volume":"6","author":"B Thewes","year":"2005","unstructured":"Thewes B, Meiser B, Duric VM, Stockler MR, Taylor A, Stuart-Harris R, Links M, Wilcken N, McLachlan SA, Phillips KA, Beith J, Boyle F, Friedlander ML (2005) What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Lancet Oncol 6:581\u2013588","journal-title":"Lancet Oncol"},{"key":"9703_CR86","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/annonc\/mdi370","volume":"16","author":"VM Duric","year":"2005","unstructured":"Duric VM, Stockler MR, Heritier S, Boyle F, Beith J, Sullivan A, Wilcken N, Coates AS, Simes RJ (2005) Patients\u2019 preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Ann Oncol 16:1786\u20131794","journal-title":"Ann Oncol"},{"key":"9703_CR87","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1200\/JCO.2004.06.109","volume":"22","author":"SJ Jansen","year":"2004","unstructured":"Jansen SJ, Otten W, Stiggelbout AM (2004) Review of determinants of patients\u2019 preferences for adjuvant therapy in cancer. J Clin Oncol 22:3181\u20133190","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"9703_CR88","first-page":"S24","volume":"100","author":"JM Dixon","year":"2006","unstructured":"Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, Dixon OM, Folkerd E, McCaig F, Cameron D, Dowsett M, Langridge C, A\u2019Hern R, Fallowfield LJ (2006) Anastrozole and letrozole an investigation and comparison of quality of life, tolerability and morbidity. Breast Cancer Res Treat 100(suppl 1):S24. Abstract 105","journal-title":"Breast Cancer Res Treat"},{"key":"9703_CR89","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00432-005-0668-x","volume":"131","author":"M Kaufmann","year":"2005","unstructured":"Kaufmann M, Rody A (2005) Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy. J Cancer Res Clin Oncol 131:487\u2013494","journal-title":"J Cancer Res Clin Oncol"},{"key":"9703_CR90","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","volume":"349","author":"PE Goss","year":"2003","unstructured":"Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793\u20131802","journal-title":"N Engl J Med"},{"key":"9703_CR91","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1023\/A:1013128213451","volume":"12","author":"W Eiermann","year":"2001","unstructured":"Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M, Borgs M; Letrozole Neo-Adjuvant Breast Cancer Study Group (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 12:1527\u20131532","journal-title":"Ann Oncol"},{"key":"9703_CR92","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.breast.2005.07.009","volume":"15","author":"C Abrial","year":"2005","unstructured":"Abrial C, Mouret-Reynier MA, Cure H, Feillel V, Leheurteur M, Lemery S, Le Bouedec G, Durando X, Dauplat J, Chollet P (2005) Neoadjuvant endocrine therapy in breast cancer. Breast 15:9\u201319","journal-title":"Breast"},{"key":"9703_CR93","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1023\/A:1010669403283","volume":"66","author":"JM Dixon","year":"2001","unstructured":"Dixon JM, Love CD, Bellamy CO, Cameron DA, Leonard RC, Smith H, Miller WR (2001) Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 66:191\u2013199","journal-title":"Breast Cancer Res Treat"},{"key":"9703_CR94","unstructured":"Renshaw L, Murray J, Young O, Cameron D, Miller WR, Dixon JM (2004) Is there an optimal duration of neoadjuvant letrozole therapy? Presented at the 27th Annual San Antonio Breast Cancer Symposium, 8\u201311 December 2004. Abstract 405"},{"key":"9703_CR95","first-page":"6523","volume":"63","author":"MJ Ellis","year":"2003","unstructured":"Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Janicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB, Miller WR (2003) Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1\/2 expression status. Cancer Res 63:6523\u20136531","journal-title":"Cancer Res"},{"key":"9703_CR96","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1200\/JCO.2005.04.3034","volume":"24","author":"MJ Ellis","year":"2006","unstructured":"Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM (2006) Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 24:3019\u20133025","journal-title":"J Clin Oncol"},{"key":"9703_CR97","unstructured":"Murray J, Young O, Renshaw L, White S, Prescot RJ, Krause A, Evans DB, Salem R, Cameron D, Dowsett M, Miller WR, Dixon JM (2004) Letrozole and anastrozole: a pre-operative study of their effects on ER positive breast cancers in postmenopausal women. Presented at the 27th Annual San Antonio Breast Cancer Symposium, 8\u201311 December 2004. Abstract 406"},{"key":"9703_CR98","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1158\/1078-0432.CCR-04-0057","volume":"15;10","author":"L Zhu","year":"2004","unstructured":"Zhu L, Chow LW, Loo WT, Guan XY, Toi M (2004) Her2\/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial. Clin Cancer Res 15;10:4639\u20134644","journal-title":"Clin Cancer Res"},{"key":"9703_CR99","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","volume":"359","author":"M Baum","year":"2002","unstructured":"Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T; ATAC Trialists\u2019 Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131\u20132139. Erratum in: Lancet 2002;360:1520","journal-title":"Lancet"},{"key":"9703_CR100","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.2005.09.121","volume":"23","author":"EP Winer","year":"2005","unstructured":"Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619\u2013629","journal-title":"J Clin Oncol"},{"key":"9703_CR101","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/jnci\/dji250","volume":"97","author":"PE Goss","year":"2005","unstructured":"Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262\u20131271","journal-title":"J Natl Cancer Inst"},{"issue":"suppl 1","key":"9703_CR102","first-page":"S10","volume":"94","author":"PE Goss","year":"2005","unstructured":"Goss PE, Ingle JN, Palmer MJ, Shepherd LE, Tu D (2005) Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs. placebo) post unblinding. Breast Cancer Res Treat 94(suppl 1):S10. Abstract 16","journal-title":"Breast Cancer Res Treat"},{"key":"9703_CR103","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1212\/01.WNL.0000140491.54664.50","volume":"63","author":"CD Bushnell","year":"2004","unstructured":"Bushnell CD, Goldstein LB (2004) Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology 63:1230\u20131233","journal-title":"Neurology"},{"key":"9703_CR104","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/annonc\/mdi326","volume":"16","author":"A Goldhirsch","year":"2005","unstructured":"Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ; Panel members (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569\u20131583","journal-title":"Ann Oncol"},{"key":"9703_CR105","unstructured":"AGO Breast Commission (2007) Diagnostic and treatment of patients with primary and metastatic breast cancer. http:\/\/www.ago-online.de. Latest update July 17, 2007"},{"issue":"suppl 1","key":"9703_CR106","first-page":"S13","volume":"94","author":"G Viale","year":"2005","unstructured":"Viale G, Regan M, Dell\u2019Orto P, Del Curto B, Braye S, Orosz Z, Brown R, Olszewski WP, Knox F, Oehlschlegel C, Th\u00fcrlimann B; the BIG 1\u201398 Collaborative International Breast Cancer Study Group (2005) Central review of ER, PgR and HER-2 in BIG 1\u201398 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res Treat 94(suppl 1):S13. Abstract 44","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 2","key":"9703_CR107","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.3816\/CBC.2006.s.003","volume":"6","author":"AM Wardley","year":"2006","unstructured":"Wardley AM (2006) Emerging data on optimal adjuvant endocrine therapy: Breast International Group trial 1\u201398\/MA.17. Clin Breast Cancer 6(suppl 2):S45\u2013S50","journal-title":"Clin Breast Cancer"},{"key":"9703_CR108","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","volume":"366","author":"R Jakesz","year":"2005","unstructured":"Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J; ABCSG, the GABG (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2\u00a0years\u2019 adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455\u2013462","journal-title":"Lancet"},{"key":"9703_CR109","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.1200\/JCO.2005.04.120","volume":"23","author":"F Boccardo","year":"2005","unstructured":"Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P (2005) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 23:5138\u20135147","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"9703_CR110","first-page":"S11","volume":"94","author":"W Jonat","year":"2005","unstructured":"Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Jakesz R (2005) Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: a meta-analysis of the ARNO 95 trial, ABCSG Trial 8, and the ITA trial. Breast Cancer Res Treat 94(suppl 1):S11. Abstract 18","journal-title":"Breast Cancer Res Treat"},{"issue":"18S","key":"9703_CR111","first-page":"14s","volume":"24","author":"M Kaufmann","year":"2006","unstructured":"Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I, Von Minckwitz G, on behalf of the German Adjuvant Breast Cancer Group (2006) Survival benefit of switching to anastrozole after 2\u00a0years\u2019 treatment with tamoxifen versus continued tamoxifen therapy: the ARNO 95 study. J Clin Oncol 24(18S):14s. Abstract 547","journal-title":"J Clin Oncol"},{"key":"9703_CR112","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1523-5394.2001.009005237.x","volume":"9","author":"SM Johnson Vickberg","year":"2001","unstructured":"Johnson Vickberg SM (2001) Fears about breast cancer recurrence. Cancer Pract 9:237\u2013243","journal-title":"Cancer Pract"},{"key":"9703_CR113","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.2004.09.070","volume":"22","author":"SK Chia","year":"2004","unstructured":"Chia SK, Speers CH, Bryce CJ, Hayes MM, Olivotto IA (2004) Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 22:1630\u20131637","journal-title":"J Clin Oncol"},{"issue":"3 Pt 2","key":"9703_CR114","doi-asserted-by":"crossref","first-page":"1056s","DOI":"10.1158\/1078-0432.CCR-05-2185","volume":"12","author":"TJ Whelan","year":"2006","unstructured":"Whelan TJ, Pritchard KI (2006) Managing patients on endocrine therapy: focus on quality-of-life issues. Clin Cancer Res 12(3 Pt 2):1056s\u20131060s","journal-title":"Clin Cancer Res"},{"key":"9703_CR115","doi-asserted-by":"crossref","first-page":"6931","DOI":"10.1200\/JCO.2005.11.181","volume":"23","author":"TJ Whelan","year":"2005","unstructured":"Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ, Martino S, Muss HB (2005) Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5\u00a0years of tamoxifen in postmenopausal women. J Clin Oncol 23:6931\u20136940","journal-title":"J Clin Oncol"},{"key":"9703_CR116","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/annonc\/mdl030","volume":"17","author":"A Glaus","year":"2006","unstructured":"Glaus A, Boehme Ch, Thurlimann B, Ruhstaller T, Hsu Schmitz SF, Morant R, Senn HJ, von Moos R (2006) Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Ann Oncol 17:801\u2013806","journal-title":"Ann Oncol"},{"key":"9703_CR117","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10549-006-9193-0","volume":"99","author":"TL Lash","year":"2006","unstructured":"Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99:215\u2013220","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 9","key":"9703_CR118","first-page":"ix100","volume":"17","author":"RJ Thomas","year":"2006","unstructured":"Thomas RJ, Marshall C, Williams M, Walker LG (2006) Switching to adjuvant letrozole improves hot flushes, mood, and quality of life in the tamoxifen intolerant subgroup. Ann Oncol 17(suppl 9):ix100. Abstract 264P","journal-title":"Ann Oncol"},{"key":"9703_CR119","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1200\/JCO.2005.05.4882","volume":"24","author":"EA Perez","year":"2006","unstructured":"Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE (2006) Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 24:3629\u20133635","journal-title":"J Clin Oncol"},{"key":"9703_CR120","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","volume":"25","author":"A Brufsky","year":"2007","unstructured":"Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA (2007) Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25:829\u2013836","journal-title":"J Clin Oncol"},{"issue":"2","key":"9703_CR121","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1359-6349(06)80035-2","volume":"4","author":"N Bundred","year":"2006","unstructured":"Bundred N, Campbell I, Coleman R, DeBoer R, Eidtmann H, Frassolati A, Llombart A, Monnier A, Neven P, Dias R (2006) Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZOFAST study). Eur J Cancer Suppl 4(2):48. Abstract 12","journal-title":"Eur J Cancer Suppl"},{"issue":"18S","key":"9703_CR122","first-page":"5s","volume":"24","author":"RE Coleman","year":"2006","unstructured":"Coleman RE, on behalf of the ATAC Trialists\u2019 Group (2006) Effect of anastrozole on bone mineral density: 5-year results from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. J Clin Oncol 24(18S):5s. Abstract 511","journal-title":"J Clin Oncol"},{"issue":"18S","key":"9703_CR123","first-page":"15s","volume":"24","author":"A Buzdar","year":"2006","unstructured":"Buzdar A et al behalf of the ATAC Trialists\u2019 Group (2006) Clinical features of joint symptoms observed in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. J Clin Oncol 24(18S):15s. Abstract 551","journal-title":"J Clin Oncol"},{"key":"9703_CR124","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1200\/JCO.1999.17.8.2371","volume":"17","author":"PA Ganz","year":"1999","unstructured":"Ganz PA, Desmond KA, Belin TR, Meyerowitz BE, Rowland JH (1999) Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 17:2371\u20132380","journal-title":"J Clin Oncol"},{"key":"9703_CR125","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/13697130500487224","volume":"9","author":"P Gupta","year":"2006","unstructured":"Gupta P, Sturdee DW, Palin SL, Majumder K, Fear R, Marshall T, Paterson I (2006) Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. Climacteric 9:49\u201358","journal-title":"Climacteric"},{"key":"9703_CR126","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.2005.04.2499","volume":"24","author":"SR Burwell","year":"2006","unstructured":"Burwell SR, Case LD, Kaelin C, Avis NE (2006) Sexual problems in younger women after breast cancer surgery. J Clin Oncol 24:2815\u20132821","journal-title":"J Clin Oncol"},{"key":"9703_CR127","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/jnci\/92.13.1054","volume":"92","author":"PA Ganz","year":"2000","unstructured":"Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR (2000) Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst 92:1054\u20131064","journal-title":"J Natl Cancer Inst"},{"key":"9703_CR128","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/annonc\/mdj127","volume":"17","author":"A Kendall","year":"2006","unstructured":"Kendall A, Dowsett M, Folkerd E, Smith I (2006) Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 17:584\u2013587","journal-title":"Ann Oncol"},{"key":"9703_CR129","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/01.gme.0000168061.32917.83","volume":"13","author":"SR Davis","year":"2006","unstructured":"Davis SR, Goldstat R, Papalia MA, Shah S, Kulkarni J, Donath S, Bell RJ (2006) Effects of aromatase inhibition on sexual function and well-being in postmenopausal women treated with testosterone: a randomized, placebo-controlled trial. Menopause 13:37\u201345","journal-title":"Menopause"},{"key":"9703_CR130","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/sj.bjc.6603258","volume":"95","author":"G Francini","year":"2006","unstructured":"Francini G, Petrioli R, Montagnani A, Cadirni A, Campagna S, Francini E, Gonnelli S (2006) Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Br J Cancer 95:153\u2013158","journal-title":"Br J Cancer"},{"key":"9703_CR131","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1470-2045(06)70767-7","volume":"7","author":"A Buzdar","year":"2006","unstructured":"The Arimidex, Tamoxifen, Alone or in Combination Trialists\u2019 Group, Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J, Locker GY, Nabholtz JM (2006) Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7:633\u2013643","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"9703_CR132","first-page":"S1001","volume":"94","author":"E McCloskey","year":"2005","unstructured":"McCloskey E, Eastell R, Lakner G, Miyamoto A, Clack G (2005) Initial results from the LEAP study: the first direct comparison of safety parameters between aromatase inhibitors in healthy postmenopausal women. Breast Cancer Res Treat 94(suppl 1):S1001. Abstract 2052","journal-title":"Breast Cancer Res Treat"},{"key":"9703_CR133","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/annonc\/mdi158","volume":"16","author":"KM Wasan","year":"2005","unstructured":"Wasan KM, Goss PE, Pritchard PH, Shepherd L, Palmer MJ, Liu S, Tu D, Ingle JN, Heath M, Deangelis D, Perez EA (2005) The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5\u00a0years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 16:707\u2013715","journal-title":"Ann Oncol"},{"issue":"16S","key":"9703_CR134","first-page":"33s","volume":"23","author":"M Paley","year":"2005","unstructured":"Paley M, Love N, Carlson R, Tripathy D, Kaderman R, Paley D, Dvorkin J, Ziel K (2005) Preferences for oral and parenteral antitumor therapy: a survey of 260 patients with metastatic breast cancer. J Clin Oncol 23(16S):33s. Abstract 619","journal-title":"J Clin Oncol"},{"key":"9703_CR135","unstructured":"GAEA press release (2006) Large European survey reveals critical gaps in breast cancer patient education and communication. http:\/\/www.medicalnewstoday.com\/medicalnews.php?newsid=53364 Cited 17 January 2007"},{"issue":"suppl 9","key":"9703_CR136","first-page":"ix99","volume":"17","author":"Y Wengstrom","year":"2006","unstructured":"Wengstrom Y, Alberto Costa, Jan Koedam, Vasoulla Georgiou (2006) Women\u2019s experience and knowledge of adjuvant Endocrine therapy (AET) for early breast cancer (bc): a European survey. Ann Oncol 17(suppl 9):ix99. Abstract 262P","journal-title":"Ann Oncol"},{"key":"9703_CR137","unstructured":"Femara Prescribing Information (2005) Novartis"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-007-9703-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-007-9703-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-007-9703-8.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-007-9703-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T19:08:17Z","timestamp":1630436897000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-007-9703-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":137,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["9703"],"URL":"https:\/\/doi.org\/10.1007\/s10549-007-9703-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10]]},"assertion":[{"value":"23 January 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}